Combination of Ifosfamide,Methotrexate, VP-16, and Bleomycin (IMV-BLEO) as Salvage Therapy for Non-Hodgkin’s Lymphoma

Publisher Website
Google Scholar
Abstract
SummaryIn an ongoing study, 29 patients with non-Hodgkin’s lymphoma (NHL), which was resistant to CHOP treatment were treated with IMV-BLEO combination therapy. Twelve patients (41%) achieved complete remission, 3 with NHL of low- and 9 of high-grade malignancy. Six patients had a partial remission. With a median follow-up of 12 months so far, median relapse-free survival time for patients entering complete remission is 9 months. Median survival time for the whole group is 16 months. Toxicity was usually mild. We conclude that IMV-BLEO is an effective and well tolerated treatment in CHOP-resistant NHL.

This publication has 0 references indexed in Scilit: